{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:43:57Z","timestamp":1792100637392,"version":"4.4.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072835"],"award-info":[{"award-number":["82072835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","award":["M0366"],"award-info":[{"award-number":["M0366"]}],"id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015226","name":"Shengjing Hospital","doi-asserted-by":"publisher","award":["202205"],"award-info":[{"award-number":["202205"]}],"id":[{"id":"10.13039\/501100015226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.biopha.2024.116152","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T05:33:00Z","timestamp":1705296780000},"page":"116152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy"],"prefix":"10.1016","volume":"171","author":[{"given":"Xiangyun","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puguang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0014-9182","authenticated-orcid":false,"given":"Kefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.biopha.2024.116152_bib1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update [J]","volume":"38","author":"Richters","year":"2020","journal-title":"World J. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib2","first-page":"17","article-title":"Cancer statistics, 2023 [J]","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 Updated European association of urology guidelines on metastatic urothelial carcinoma [J]","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116152_bib4","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.biopha.2024.116152_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/cells11050803","article-title":"Antibody-drug conjugates in urothelial carcinoma: a new therapeutic opportunity moves from bench to bedside [J]","volume":"11","author":"Ungaro","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2024.116152_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211047352","article-title":"Metastatic urothelial cancer: a rapidly changing treatment landscape [J]","volume":"13","author":"Stecca","year":"2021","journal-title":"Ther. Adv. Med Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2217\/imt-2020-0128","article-title":"From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer [J]","volume":"13","author":"Tambaro","year":"2021","journal-title":"Immunotherapy"},{"issue":"10364","key":"10.1016\/j.biopha.2024.116152_bib8","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments [J]","volume":"400","author":"Comperat","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/03915603221139907","article-title":"Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives [J]","volume":"90","author":"Iacovelli","year":"2023","journal-title":"Urologia"},{"issue":"7","key":"10.1016\/j.biopha.2024.116152_bib10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/14712598.2020.1789096","article-title":"Antibody-drug conjugates for the treatment of urothelial carcinoma [J]","volume":"21","author":"Ravi","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2024.116152_bib11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00345-020-03502-7","article-title":"Immune checkpoint inhibition in upper tract urothelial carcinoma [J]","volume":"39","author":"Califano","year":"2021","journal-title":"World J. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update [J]","volume":"84","author":"Roupret","year":"2023","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.biopha.2024.116152_bib13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial [J]","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2024.116152_bib14","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN guidelines(R) insights: bladder cancer, version 2.2022 [J]","volume":"20","author":"Flaig","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.biopha.2024.116152_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103534","article-title":"Immuno-oncology therapy in metastatic bladder cancer: a systematic review and network meta-analysis [J]","volume":"169","author":"Chierigo","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.biopha.2024.116152_bib16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology [J]","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"20","key":"10.1016\/j.biopha.2024.116152_bib17","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy [J]","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"issue":"29","key":"10.1016\/j.biopha.2024.116152_bib18","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy [J]","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.biopha.2024.116152_bib19","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors [J]","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin. Cancer Res"},{"issue":"22","key":"10.1016\/j.biopha.2024.116152_bib20","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors [J]","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116152_bib21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/1535-7163.MCT-15-0570","article-title":"Development of ASG-15ME, a novel antibody-drug conjugate targeting SLITRK6, a new urothelial cancer biomarker [J]","volume":"15","author":"Morrison","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.biopha.2024.116152_bib22","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates [J]","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"23","key":"10.1016\/j.biopha.2024.116152_bib23","doi-asserted-by":"crossref","first-page":"21159","DOI":"10.1002\/cam4.6680","article-title":"Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: a multicenter, retrospective clinical study","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib25","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy [J]","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates [J]","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib27","article-title":"Targeting integrin pathways: mechanisms and advances in therapy [J]","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2024.116152_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2021.11.016","article-title":"Antibody drug conjugates in non-small cell lung cancer: an emerging therapeutic approach [J]","volume":"163","author":"Marks","year":"2022","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets [J]","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2024.116152_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174516","article-title":"Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy [J]","volume":"911","author":"Chatterjee","year":"2021","journal-title":"Eur. J. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2024.116152_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma [J]","volume":"18","author":"Heath","year":"2021","journal-title":"Nat. Rev. Urol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116152_bib32","first-page":"772","article-title":"Enfortumab vedotin-ejfv: a first-in-class anti-nectin-4 antibody-drug conjugate for the management of urothelial carcinoma [J]","volume":"55","author":"Halford","year":"2021","journal-title":"Ann. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2024.116152_bib33","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14712598.2021.1865910","article-title":"Enfortumab vedotin - next game-changer in urothelial cancer [J]","volume":"21","author":"Maas","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2024.116152_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-023-00814-6","article-title":"Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma [J]","author":"Ghatalia","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer [J]","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.biopha.2024.116152_bib36","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer [J]","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116152_bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.urolonc.2022.07.006","article-title":"Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: a scoping review [J]","volume":"40","author":"Padua","year":"2022","journal-title":"Urol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy [J]","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"issue":"4","key":"10.1016\/j.biopha.2024.116152_bib39","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role [J]","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2024.116152_bib40","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up [J]","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2024.116152_bib41","doi-asserted-by":"crossref","first-page":"a041333","DOI":"10.1101\/cshperspect.a041333","article-title":"Emerging therapies for breast cancer [J]","volume":"13","author":"Goel","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med"},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer [J]","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.biopha.2024.116152_bib43","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: first approval [J]","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.biopha.2024.116152_bib44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2022.58.10.3408812","article-title":"Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors [J]","volume":"58","author":"Hu","year":"2022","journal-title":"Drugs Today (Barc. )"},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma [J]","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.biopha.2024.116152_bib46","article-title":"A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.biopha.2024.116152_bib47","volume":"40","author":"Sheng","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib48","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/fon-2021-0550","article-title":"Trastuzumab deruxtecan for HER2+ advanced breast cancer [J]","volume":"18","author":"Lee","year":"2022","journal-title":"Future Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2024.116152_bib50","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity [J]","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.biopha.2024.116152_bib51","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors [J]","volume":"22","author":"Indini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.116152_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer [J]","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"issue":"21","key":"10.1016\/j.biopha.2024.116152_bib53","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper [J]","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"48","key":"10.1016\/j.biopha.2024.116152_bib54","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target [J]","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.biopha.2024.116152_bib55","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ddr.21870","article-title":"Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors [J]","volume":"82","author":"Liao","year":"2021","journal-title":"Drug Dev. Res"},{"issue":"28","key":"10.1016\/j.biopha.2024.116152_bib56","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.2217\/fon-2022-0407","article-title":"Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon [J]","volume":"18","author":"Furlanetto","year":"2022","journal-title":"Future Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2024.116152_bib57","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14712598.2020.1757067","article-title":"Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy [J]","volume":"20","author":"Goldenberg","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2024.116152_bib58","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-20-3119","article-title":"FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer [J]","volume":"27","author":"Wahby","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2024.116152_bib59","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40259-023-00606-5","article-title":"Antibody-drug conjugates in the treatment of urothelial cancer [J]","volume":"37","author":"Singh","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.biopha.2024.116152_bib60","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2147\/CMAR.S287904","article-title":"Treatment options for metastatic urothelial carcinoma after first-line chemotherapy [J]","volume":"14","author":"Tassinari","year":"2022","journal-title":"Cancer Manag Res"},{"issue":"6_suppl","key":"10.1016\/j.biopha.2024.116152_bib61","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.434","article-title":"TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens","volume":"40","author":"Grivas","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116152_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103683","article-title":"Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management [J]","volume":"174","author":"Bellmunt","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116152_bib63","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy [J]","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib64","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody-drug conjugates (ADCs) for cancer therapy [J]","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int"},{"issue":"19","key":"10.1016\/j.biopha.2024.116152_bib65","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer [J]","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.biopha.2024.116152_bib66","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/biom10030360","article-title":"Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations [J]","volume":"10","author":"Shim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2024.116152_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development [J]","volume":"229","author":"Jin","year":"2022","journal-title":"Pharm. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2024.116152_bib68","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress [J]","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2024.116152_bib69","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion [J]","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2024.116152_bib70","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s11912-022-01334-9","article-title":"Antibody-drug conjugates in non-small cell lung cancer: emergence of a novel therapeutic class [J]","volume":"24","author":"Marks","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib71","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma [J]","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116152_bib72","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/oncolo\/oyad233","article-title":"The evolving landscape of immune checkpoint inhibitors and antibody drug conjugates in the treatment of early-stage breast cancer [J]","volume":"28","author":"Bhardwaj","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2024.116152_bib73","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2021.12.002","article-title":"Antibody-drug conjugates: a promising novel therapeutic approach in lung cancer [J]","volume":"163","author":"Desai","year":"2022","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2024.116152_bib74","article-title":"Antibody-drug conjugates in prostate cancer: a systematic review [J]","volume":"15","author":"Sardinha","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib75","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116152_bib76","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy [J]","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discov."},{"issue":"43","key":"10.1016\/j.biopha.2024.116152_bib77","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390094","article-title":"Rise of antibody-drug conjugates: the present and future [J]","author":"Shastry","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"19","key":"10.1016\/j.biopha.2024.116152_bib78","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.3390\/cancers14194616","article-title":"Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in patients with hepatocellular carcinoma [J]","volume":"14","author":"De Lorenzo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.biopha.2024.116152_bib79","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade [J]","volume":"185","author":"Morad","year":"2022","journal-title":"Cell"},{"issue":"15_Supplement","key":"10.1016\/j.biopha.2024.116152_bib80","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1158\/1538-7445.AM2015-2469","article-title":"Abstract 2469: Brentuximab vedotin-mediated immunogenic cell death","volume":"75","author":"Gardai","year":"2015","journal-title":"Cancer Res"},{"issue":"12_Supplement","key":"10.1016\/j.biopha.2024.116152_bib81","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1158\/1538-7445.AM2022-2638","article-title":"Abstract 2638: sacituzumab govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): translational investigation","volume":"82","author":"Bardia","year":"2022","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.biopha.2024.116152_bib82","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer [J]","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.biopha.2024.116152_bib83","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III Trial [J]","volume":"15","author":"Jotte","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib84","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial [J]","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116152_bib85","first-page":"86","article-title":"A review of cancer immunotherapy toxicity [J]","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2024.116152_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect? [J]","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2024.116152_bib87","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","article-title":"Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy [J]","volume":"452","author":"Yu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116152_bib88","doi-asserted-by":"crossref","first-page":"9527","DOI":"10.2147\/OTT.S224013","article-title":"Blocking TGF-\u03b2 signaling to enhance the efficacy of immune checkpoint inhibitor [J]","volume":"12","author":"Bai","year":"2019","journal-title":"Onco Targets Ther."},{"issue":"7693","key":"10.1016\/j.biopha.2024.116152_bib89","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. [J]","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib90","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. ] Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib91","article-title":"Combine and conquer: manganese synergizing anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers","volume":"14","author":"Yi","year":"2021","journal-title":"J. ] Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116152_bib92","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J. ] Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2024.116152_bib93","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J. ] Hematol. Oncol."},{"key":"10.1016\/j.biopha.2024.116152_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives [J]","volume":"106","author":"Nicolo","year":"2022","journal-title":"Cancer Treat. Rev."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2024.116430","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224000337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224000337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:46:43Z","timestamp":1792097203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224000337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":94,"alternative-id":["S0753332224000337"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116152","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116152"}}